Download presentation
Presentation is loading. Please wait.
Published byPascale Girard Modified over 5 years ago
1
Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI® and BRAMITOB® (Tobramycin inhalation solutions) John E. Moore, Yasunori Maeda, Colin E. Goldsmith, Jacqueline C. Rendall, J. Stuart Elborn Journal of Cystic Fibrosis Volume 9, Issue 3, Pages (May 2010) DOI: /j.jcf Copyright © 2010 Elsevier B.V. Terms and Conditions
2
Fig. 1 Determination of the coefficient of correlation (r2) calculated from the paired comparison of the in vitro antimicrobial susceptibilities of TOBI® versus BRAMITOB® performed in triplicate in 100 wildtype CF P. aeruginosa isolates. For ease of visualisation, graph ends at MIC<6μg/ml, but r2 and F-values have been calculated based on all 100 isolates tested. Journal of Cystic Fibrosis 2010 9, DOI: ( /j.jcf ) Copyright © 2010 Elsevier B.V. Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.